Get the Stockscreener App
1.53
5.56%
0.09
After Hours:
1.53
Innate Pharma Adr Stock (IPHA) Forecast
The Innate Pharma Adr (IPHA) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $3.6481, representing a +138.44% increase from the current price of $1.53. The highest analyst price target is $4.4099, and the lowest is $2.8863.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month IPHA Price Target
Average 2.6405
(+72.58% Upside)
Is Innate Pharma Adr (IPHA) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 36.24 | Neutral |
| STOCH(9,6) | 32.76 | Neutral |
| STOCHRSI(14) | 21.30 | Neutral |
| MACD(12,26) | -0.1135 | Sell |
| ADX(14) | 30.48 | Sell |
| William %R | -68.83 | Neutral |
| CCI(14) | -168.13 | Sell |
Buy: 0
Sell: 3
Neutral: 4
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
1.7587
Sell
|
1.7027
Sell
|
| MA20 |
1.8031
Sell
|
1.7981
Sell
|
| MA50 |
2.0176
Sell
|
1.9566
Sell
|
| MA100 |
2.1052
Sell
|
2.0967
Sell
|
| MA200 |
2.3196
Sell
|
2.267
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, IPHA could be considered a Strong Sell, with 17 technical analysis indicators signaling 0 Buy signals, 13 signaling Sell signals and 4 Neutral signals. This might not be a good time to consider opening new positions on IPHA, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 36.24 indicates that IPHA is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 32.76 indicates that IPHA is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 21.3 indicates that IPHA is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 30.48 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -168.13 indicates that IPHA is oversold. This means that the price has moved significantly lower than its average, indicating a potential buying opportunity.
Long-term IPHA price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Innate Pharma Adr financial reports and earnings history, Innate Pharma Adr (IPHA) stock could reach $1.0468 by 2030, $6.3489 by 2040 and $15.39 by 2050. See the projected annual prices until 2050 of the Innate Pharma Adr stock below:
- Innate Pharma Adr (IPHA) is expected to reach an average price of $6.2929 in 2035, with a high prediction of $5.4629 and a low estimate of $3.1174. This indicates an $311.30% rise from the last recorded price of $1.53.
- Innate Pharma Adr (IPHA) stock is projected to chart a bullish course in 2040, with an average price target of $6.6159, representing an $332.41% surge from its current level. The forecast ranges from a conservative $6.6159 to a sky-high $6.3489.
- Our analysts predict Innate Pharma Adr (IPHA) to jump 665.72% by 2045, soaring from $11.63 to an average price of $11.72, potentially reaching $11.47. While $11.63 is the low estimate, the potential upside is significant.
- Innate Pharma Adr (IPHA) stock is expected to climb by 2050, reaching an average of $15.56, a $916.70% jump from its current level. However, a wide range of estimates exists, with high and low targets of $15.39 and $5.1756, respectively, highlighting the market's uncertainty.
Innate Pharma Adr Stock (IPHA) Year by Year Forecast
Innate Pharma Adr Stock (IPHA) Price Forecast for 2024
Our forecast for IPHA stock price in 2024 now indicates an average price target of $2.4267 with a high forecast of $4.7424 and a low forecast of $0.111. The average prediction reflects an increase of +58.61% from the last recorded price of $1.53.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| December, 2024 | $4.4099 | $2.8863 | $4.4099 | +188.23% |
Innate Pharma Adr Stock (IPHA) Price Forecast for 2025
Innate Pharma Adr Stock (IPHA) is expected to reach an average price of $2.6405 in 2025, with a high prediction of $4.8978 and a low estimate of $0.3832. This indicates an +72.58% rise from the last recorded price of $1.53.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $2.8823 | $2.6193 | $4.8978 | +88.38% |
| February, 2025 | $3.1808 | $2.7772 | $4.2229 | +107.89% |
| March, 2025 | $2.8123 | $2.6923 | $3.5044 | +83.81% |
| April, 2025 | $3.0117 | $2.3502 | $3.4359 | +96.84% |
| May, 2025 | $0.6982 | $0.3832 | $3.2695 | -54.37% |
| June, 2025 | $1.0347 | $0.6111 | $1.2768 | -32.37% |
| July, 2025 | $1.8041 | $0.6804 | $2.1881 | +17.91% |
| August, 2025 | $1.1456 | $1.0356 | $2.6777 | -25.13% |
| September, 2025 | $1.6171 | $0.9834 | $1.9171 | +5.69% |
| October, 2025 | $1.3764 | $0.9907 | $1.9278 | -10.04% |
| November, 2025 | $1.608 | $1.2522 | $1.738 | +5.09% |
| December, 2025 | $1.4773 | $0.9995 | $1.8358 | -3.44% |
Innate Pharma Adr Stock (IPHA) Price Forecast for 2026
The predicted value for Innate Pharma Adr (IPHA) in 2026 is set at an average of $4.7238. Estimates vary from a peak of $9.2164 to a trough of $0.2312, indicating an +208.74% surge from the present price of $1.53.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $1.125 | $0.921 | $1.4658 | -26.47% |
| February, 2026 | $1.2803 | $0.7425 | $1.4503 | -16.32% |
| March, 2026 | $0.6918 | $0.414 | $1.3682 | -54.78% |
| April, 2026 | $0.5209 | $0.2312 | $0.7432 | -65.95% |
| May, 2026 | $0.8827 | $0.4011 | $0.9427 | -42.31% |
| June, 2026 | $3.9742 | $0.8706 | $9.2164 | +159.75% |
| July, 2026 | $2.8936 | $2.8236 | $4.4821 | +89.12% |
| August, 2026 | $2.3551 | $2.2951 | $3.3693 | +53.93% |
| September, 2026 | $2.6645 | $1.6387 | $2.7645 | +74.15% |
| October, 2026 | $1.946 | $1.8202 | $2.7402 | +27.19% |
| November, 2026 | $1.2675 | $0.8719 | $1.9439 | -17.16% |
| December, 2026 | $0.3169 | $0.3169 | $1.3054 | -79.29% |
Innate Pharma Adr Stock (IPHA) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Innate Pharma Adr (IPHA) is $0.9389, with a high forecast of $1.8664 and a low forecast of $0.0113. This indicates an -38.64% decrease from the last price of $1.53.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $0.8784 | $0.1548 | $1.0584 | -42.59% |
| February, 2027 | $0.6199 | $0.5029 | $1.0763 | -59.48% |
| March, 2027 | $0.6293 | $0.2178 | $0.7714 | -58.87% |
| April, 2027 | $0.3792 | $0.2571 | $0.7789 | -75.21% |
| May, 2027 | $0.5623 | $0.1386 | $0.6344 | -63.25% |
| June, 2027 | $0.5917 | $0.3051 | $0.8758 | -61.33% |
| July, 2027 | $0.3732 | $0.3232 | $0.8595 | -75.61% |
| August, 2027 | $0.2453 | $0.0268 | $0.9068 | -83.96% |
| September, 2027 | $0.056 | $0.106 | $0.0896 | -96.34% |
| October, 2027 | $0.0455 | $0.0162 | $0.3477 | -97.02% |
| November, 2027 | $0.243 | $0.0113 | $0.247 | -84.12% |
| December, 2027 | $1.4664 | $0.2249 | $1.8664 | -4.16% |
Innate Pharma Adr Stock (IPHA) Price Forecast for 2028
In 2028, Innate Pharma Adr (IPHA) is projected to reach an average price of $0.8904, with a high projection of $1.7043 and a low estimate of $0.0766. This indicates an -41.80% fall from the last price of $1.53.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $1.2479 | $1.1434 | $1.7043 | -18.44% |
| February, 2028 | $0.7694 | $0.3516 | $1.4494 | -49.71% |
| March, 2028 | $1.1638 | $0.4831 | $1.3888 | -23.93% |
| April, 2028 | $1.0303 | $0.7503 | $1.3967 | -32.66% |
| May, 2028 | $0.9997 | $0.8282 | $1.0982 | -34.66% |
| June, 2028 | $1.1762 | $1.0126 | $1.6554 | -23.12% |
| July, 2028 | $1.1694 | $1.0091 | $1.4148 | -23.57% |
| August, 2028 | $0.9221 | $0.8321 | $1.1963 | -39.73% |
| September, 2028 | $1.1736 | $0.885 | $1.3457 | -23.29% |
| October, 2028 | $0.5501 | $0.3351 | $1.2415 | -64.05% |
| November, 2028 | $0.6445 | $0.0766 | $0.993 | -57.88% |
| December, 2028 | $0.746 | $0.5343 | $0.9381 | -51.24% |
Innate Pharma Adr Stock (IPHA) Price Forecast for 2029
The 2029 price forecast for Innate Pharma Adr Stock (IPHA) is $1.0534 on average, with a high prediction of $2.052 and a low estimate of $0.0548. This represents an -31.15% decrease from the previous price of $1.53.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $1.2654 | $0.5814 | $1.4134 | -17.30% |
| February, 2029 | $1.0569 | $0.8487 | $1.3032 | -30.92% |
| March, 2029 | $1.0684 | $0.7047 | $1.0826 | -30.17% |
| April, 2029 | $0.9649 | $0.7562 | $1.132 | -36.94% |
| May, 2029 | $0.9192 | $0.6979 | $1.6214 | -39.92% |
| June, 2029 | $1.06 | $0.7551 | $1.0729 | -30.72% |
| July, 2029 | $0.827 | $1.137 | $1.1027 | -45.95% |
| August, 2029 | $1.1282 | $1.024 | $0.8155 | -26.26% |
| September, 2029 | $0.1748 | $0.0548 | $1.2448 | -88.58% |
| October, 2029 | $0.7235 | $0.1237 | $0.842 | -52.71% |
| November, 2029 | $0.2265 | $0.2265 | $1.0708 | -85.19% |
| December, 2029 | $0.1105 | $0.8305 | $2.052 | -92.78% |
Innate Pharma Adr Stock (IPHA) Price Forecast for 2030
Innate Pharma Adr Stock (IPHA) is expected to reach an average price of $1.2319 in 2030, with a high forecast of $2.3721 and a low forecast of $0.0917. This signifies an -19.48% decrease from the last price of $1.53.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $0.8883 | $0.0917 | $1.0468 | -41.94% |
| February, 2030 | $0.6287 | $0.2544 | $1.5656 | -58.91% |
| March, 2030 | $0.1357 | $0.5157 | $0.1357 | -91.13% |
| April, 2030 | $0.4427 | $0.4384 | $0.9458 | -71.07% |
| May, 2030 | $0.1939 | $0.1312 | $0.2588 | -87.33% |
| June, 2030 | $0.3019 | $0.1867 | $0.2218 | -80.27% |
| July, 2030 | $2.3921 | $2.4521 | $2.3721 | +56.35% |
| August, 2030 | $1.8491 | $2.3749 | $2.0606 | +20.86% |
| September, 2030 | $0.6161 | $1.1857 | $1.8334 | -59.73% |
| October, 2030 | $1.8274 | $0.8204 | $1.6874 | +19.44% |
| November, 2030 | $1.5444 | $1.6301 | $1.6316 | +0.94% |
| December, 2030 | $1.5814 | $1.6171 | $1.5486 | +3.36% |
4.27%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):